Sad man sitting head in hands sitting in the dark with low light environment. Treatment with lofexidine may provide better control of the symptoms of opioid withdrawal syndrome compared with placebo.

LAS VEGAS -- Lofexidine (Lucemyra), an alpha-2 adrenergic agonist, reduced the severity of opioid withdrawal and retained more people through the withdrawal process, researchers reported here. A ...

A US Food and Drug Administration (FDA) advisory committee has recommended approval of lofexidine hydrochloride, a nonopioid, for the mitigation of symptoms in the setting of abrupt opioid withdrawal.

MIAMI — Lofexidine (Lucemyra, US Worldmeds), which has been in use in the United Kingdom for more than 20 years, is now available in the United States. The drug is used in the management of symptoms ...

opioid-withdrawal-symptoms_G_948878334 Lofexidine may help patients with opioid withdrawal symptoms or difficulty with opioid discontinuation. The following article is part of The Clinical Advisor’s ...

LOUISVILLE, Ky.--(BUSINESS WIRE)--US WorldMeds, a Kentucky-based specialty pharmaceutical company, today announced that a recently completed Phase III clinical trial investigating the use of ...

Please provide your email address to receive an email when new articles are posted on . Results from a study presented at Psych Congress suggested that lofexidine can effectively mitigate symptoms of ...

LOUISVILLE, Ky., May 16, 2018 /PRNewswire/ -- US WorldMeds today announced that the US Food and Drug Administration (FDA) approved LUCEMYRA (lofexidine) for mitigation of opioid withdrawal symptoms to ...

Learn everything you need to know about Lofexidine-pronunciation, uses, dosage guidelines, indications, and when to take or avoid it. Get up-to-date information on side effects, precautions, warnings, ...

Review the side-effects of Lofexidine as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

ANAHEIM, CA and LOUISVILLE, KY - March 10, 2025 (NEWMEDIAWIRE) - BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of innovative treatment programs for substance abuse and related ...